News Category
Viromed Medical AG raised approximately EUR 2 million through a capital increase to finance working capital.
Scinai Immunotherapeutics has announced a $4 million private placement and warrant inducement transaction with an existing institutional investor, aim...
Nutriband Inc. (NASDAQ: NTRB) has raised approximately $1.75 million through warrant exercises, with proceeds earmarked to support the clinical develo...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to initiate a Phase 2 trial of Lucid-MS, a nov...
Okogen, Inc. has received CDSCO authorization to advance its EMERALD Phase 1/2 study of Treyegen (OKG-0303) for acute infectious conjunctivitis, poten...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., signaling its transition toward commercialization of novel mental health trea...
MindWave Innovations will deploy its MindChain infrastructure to power AQUAEChain, a platform for insured ALCI Credits, under a 12-month agreement tha...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FD...
American Fusion Inc. has moved its Texatron fusion program into active testing, reporting peak confinement pressures of 100,000 atmospheres and attrac...
Moody Capital Solutions will host its 2026 Disruptive Growth & Life Sciences Conference, a two-day event designed to connect investors with emerging a...
SuzieQ Holdings Inc., a post-quantum cryptography firm, will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Confere...
A new study reveals that treating certain emergency room patients while seated instead of waiting for a bed can significantly cut wait times, potentia...
Helus Pharma reported progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and provided fin...
Helus Pharma announced the appointment of Michael Halstead as CEO, bringing extensive biopharmaceutical leadership to guide the company through Phase ...
Ocumetics Technology Corp. has closed the second tranche of its private placement, bringing total gross proceeds to $2.95 million to fund clinical tri...
VERAXA Biotech AG shareholders approved all proposals at an Extraordinary General Meeting, including conditional share capital, a capital band through...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the c...
Gerresheimer has started operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary pharmac...
Helus Pharma has completed enrollment in its pivotal Phase 3 APPROACH trial for HLP003, an investigational psilocin analogue for major depressive diso...
Darwin AG has officially changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market presence an...
NanoViricides progresses its broad-spectrum antiviral NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, offering a pot...
Redwood AI Corp. has been included in the CSE25 Index, reflecting its position among the largest companies on the Canadian Securities Exchange and pot...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with top-line data ex...
Quantum BioPharma Ltd. is advancing Lucid-MS, a first-in-class drug candidate designed to repair myelin damage in multiple sclerosis, into Phase 2 tri...
Oncotelic Therapeutics' nanoparticle-based Deciparticle platform highlights how advanced drug delivery could unlock value from existing oncology drugs...
Quantum BioPharma Ltd. is progressing its patented drug candidate Lucid-MS, a non-immunomodulatory therapy that directly protects the myelin sheath, i...
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and potent killing o...
Redwood AI Corp. leverages proprietary AI platforms to accelerate chemistry research and development across pharmaceuticals, defense, and industrial s...
Helix BioPharma Corp. announced financial results showing a reduced net loss and increased cash reserves, driven by a private placement that extends o...
CNS Pharmaceuticals highlighted its oversubscribed $22.5 million financing and outlined its growth strategy during a virtual investor presentation, em...
Oncotelic Therapeutics and Sapu Nano have expanded their Phase 1b clinical program for Sapu003, a novel intravenous formulation of everolimus, and app...
Rising oncology drug costs and regulatory challenges are driving biotech companies toward platform-based drug-delivery technologies, with the market p...
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial progress of unbuzzd™, with an upcoming Ph...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by repairing nerve damage, while its commercial product u...
Quantum BioPharma Ltd. discusses its lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd(TM) on ...
Tonix Pharmaceuticals presented real-world data showing about 40% of fibromyalgia patients are prescribed opioids, highlighting a gap between practice...
Optimi Health Corp. praised Australia’s revised Therapeutic Goods Administration rules that broaden psilocybin and MDMA prescribing, potentially accel...
Tonix Pharmaceuticals presented real-world claims analysis at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur s...
Annovis Bio Inc. has restored its NYSE listing compliance by addressing market capitalization and stockholders' equity requirements, ensuring its comm...
Oncotelic Therapeutics (OTCQB: OTLC) has integrated approximately 28 million scientific abstracts into its proprietary PDAOAI platform, positioning it...
Sunshine Biopharma Inc. has closed a $6 million public offering, with proceeds earmarked for general corporate purposes and working capital, and poten...
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan outlined the company's precision medicine approach to cardiovascular disease and announced expansion ...
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory steps, and a letter o...
Kairos Pharma CEO Dr. John Yu will present updates on the company's oncology pipeline, including Phase 2 trial for ENV-105 in prostate cancer, at the ...
Lantern Pharma announced it will release its first-quarter 2026 financial results on May 15, providing updates on clinical trials and AI platform deve...
MindBio Therapeutics has filed patent applications for 15 novel discoveries in AI-driven voice intoxication detection, targeting high-volume regulated...
Annovis Bio CEO will present the company’s multi-protein targeting approach for Alzheimer’s at Fierce Biotech Week 2026, highlighting buntanetap’s pot...
Cardio Diagnostics Holdings Inc. is leveraging artificial intelligence and multi-omic biomarkers to improve early detection of cardiovascular disease,...
